2015
DOI: 10.1016/j.tet.2015.02.029
|View full text |Cite
|
Sign up to set email alerts
|

Expanded applicability of iridium(I) NHC/phosphine catalysts in hydrogen isotope exchange processes with pharmaceutically-relevant heterocycles

Abstract: An assessment of emerging C-H activation catalysts of the type [(COD)Ir(IMes)(PR3)]PF6 in the deuteration of N-heterocycles is divulged. Substrate scope, competition experiments, and labelling of drug type molecules have revealed PR3 = PPh3 provides a broadly more applicable and widely effective catalyst system compared to other available complexes in the present series.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
35
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
7
2

Relationship

5
4

Authors

Journals

citations
Cited by 77 publications
(37 citation statements)
references
References 26 publications
2
35
0
Order By: Relevance
“…As such, any studies which evaluate our developed catalysts in the labelling of aromatic esters should also compare them against the ability of 5 to mediate the same catalytic labelling reactions under identical conditions [19,29]. To this end, and to initiate this research programme, the labelling of a series of para-substituted ethyl benzoate derivatives 6 was examined, using our standard labelling protocol (5 mol % [Ir], 1 atm D2, 1 h) with Crabtree's catalyst 5 (Scheme 2, blue bars) and our developed catalyst systems 1b and 1a (Scheme 2, red and green bars, respectively).…”
Section: Catalyst Screening and Comparisons With Crabtree's Catalystmentioning
confidence: 99%
See 1 more Smart Citation
“…As such, any studies which evaluate our developed catalysts in the labelling of aromatic esters should also compare them against the ability of 5 to mediate the same catalytic labelling reactions under identical conditions [19,29]. To this end, and to initiate this research programme, the labelling of a series of para-substituted ethyl benzoate derivatives 6 was examined, using our standard labelling protocol (5 mol % [Ir], 1 atm D2, 1 h) with Crabtree's catalyst 5 (Scheme 2, blue bars) and our developed catalyst systems 1b and 1a (Scheme 2, red and green bars, respectively).…”
Section: Catalyst Screening and Comparisons With Crabtree's Catalystmentioning
confidence: 99%
“…Over recent years, research in our laboratory has focused on the development of iridium(I) N-heterocyclic carbene (NHC)-ligated precatalysts of the type 1, and their application in HIE via ortho-directed C-H activation protocols (2→4 via 3, Scheme 1) [6,[16][17][18][19][20][21][22]. Despite the growing list of compatible directing groups, we [23] and others [24][25][26][27] have found these developed C-H activation methods less applicable in the labelling of aromatic esters under ambient conditions.…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, to test the feasibility of this approach, we performed commonly known hydrogen isotope exchange methods on cabazitaxel 1a , docetaxel 1b, and baccatine. Unfortunately, both the commercially available Crabtree‐ and Kerr‐ catalysts as well as high temperature solid state isotopic exchange resulted in specific activities less than 10 Ci/mmol. While this may be sufficient for most pharmacokinetic studies, for our labelling experiments, we required a specific activity of at least 50 Ci/mmol …”
Section: Resultsmentioning
confidence: 99%
“…Thus, today, tritium tracers are widely used for ADME‐profiling of new drug candidates but also as a discovery tool for photoaffinity labelling and for radioligand, protein, and covalent binding assays. In particular, Kerr's catalysts 2 and 3 are widely applied for mild and selective ortho ‐labelling using a broad range of directing groups such as ketones, amides, esters, primary sulfonamides, and several heterocycles . Despite recent progress, a number of interesting functionalities, ubiquitous throughout drug motives, still present significant challenges for established HIE protocols.…”
Section: Introductionmentioning
confidence: 99%